PD -1/PD-L1 monoclonal antibody Clinical Trials
2 recruitingDrug
Early Phase 11Phase 21
Showing 1–2 of 2 trials
Recruiting
Phase 2
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07410520
Recruiting
Early Phase 1
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
Advanced Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University20 enrolled1 locationNCT06106152